This course has expired. View available courses.
Endocrinology
Beyond glycaemic management – the role of SGLT2i in the T2D treatment algorithm
With the newly-released 2020 ADS/RACGP Australian diabetes treatment guideline presents new treatment opportunities for Australian clinicians and their patients with diabetes. In this program, you will get to know the most current diabetes management guidelines, and cover the clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function.
With a focus on how to individualise diabetes treatment regimens based on patients’ risk profiles and comorbidities, this program covers how to differentiate between the different classes of glucose-lowering medicines as they pertain to specific clinical situations.
This program is supported by independent educational grants provided by Boehringer Ingelheim and Eli Lilly.
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
RACGP CPD Program
EXPIRY DATE
2022-08-09
With the newly-released 2020 ADS/RACGP Australian diabetes treatment guideline presents new treatment opportunities for Australian clinicians and their patients with diabetes. In this program, you will get to know the most current diabetes management guidelines, and cover the clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function.
With a focus on how to individualise diabetes treatment regimens based on patients’ risk profiles and comorbidities, this program covers how to differentiate between the different classes of glucose-lowering medicines as they pertain to specific clinical situations.
This program is supported by independent educational grants provided by Boehringer Ingelheim and Eli Lilly.
Faculty
Dr Anita Sharma (GP)
MBBS, FRACGP
Dr Esther Briganti (Endocrinologist)
MBBS, MClinEpi, PhD, FRACP
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Describe the 2020 Royal Australian College of General Practitioners (RACGP) diabetes management guidelines, including clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function
- Differentiate between the different classes of glucose-lowering medicines as they pertain to specific clinical situations
- Individualise diabetes treatment regimens based on patients’ risk profiles and comorbidities, including cardiovascular disease, heart failure, impaired renal function, hypertension and obesity
- Identify situations in which specific glucose-lowering medicines may be contraindicated or require cessation
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.
Activity no. 219517
Members are able to claim CPD activity points for 2 points through 'Quick log' on their RACGP CPD Dashboard.
#
of credits: 2
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Physician
Profession
2
# of credits
Learning Objectives
Upon completion of this continuing education program participants will be better able to:
- Describe the 2020 Royal Australian College of General Practitioners (RACGP) diabetes management guidelines, including clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function
- Differentiate between the different classes of glucose-lowering medicines as they pertain to specific clinical situations
- Individualise diabetes treatment regimens based on patients’ risk profiles and comorbidities, including cardiovascular disease, heart failure, impaired renal function, hypertension and obesity
- Identify situations in which specific glucose-lowering medicines may be contraindicated or require cessation
RACGP CPD Program
ACCREDITATION
Endocrinology
Learning Category
General
Topic
0
Price
2022-08-09
Expiry Date
AUS
Region/Language
Course Description
With the newly-released 2020 ADS/RACGP Australian diabetes treatment guideline presents new treatment opportunities for Australian clinicians and their patients with diabetes. In this program, you will get to know the most current diabetes management guidelines, and cover the clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function.
With a focus on how to individualise diabetes treatment regimens based on patients’ risk profiles and comorbidities, this program covers how to differentiate between the different classes of glucose-lowering medicines as they pertain to specific clinical situations.
This program is supported by independent educational grants provided by Boehringer Ingelheim and Eli Lilly.
Faculty
Dr Anita Sharma (GP)
MBBS, FRACGP
Dr Esther Briganti (Endocrinologist)
MBBS, MClinEpi, PhD, FRACP
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.
Activity no. 219517
Members are able to claim CPD activity points for 2 points through ‘Quick log’ on their RACGP CPD Dashboard.
1 hr
Duration
0
Price
2
# of credits
